Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
Jinjing Xia(Shanghai Jiao Tong University), Baohui Han(Shanghai Jiao Tong University)
Cited by 19
Related Papers
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380
Consensus for HER2 alterations testing in non-small-cell lung cancer
|ESMO Open|2022|110
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
|Lung Cancer|2014|51